sglt2 Archives - BCDiabetes

Third SGLT2 inhibitor to be marketed in Canada

Research

Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada.  Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine.  This results in increased urine volumes in all patients and a tripling […]

READ MORE

U.S. FDA warns on SGLT2 inhibitors, a class of type 2 diabetes drugs

Announcements,Research

This past Friday the US Federal Drug Administration released a warning that some newer type 2 diabetes drugs, known as SGLT2 inhibitors, may cause ketoacidosis, or dangerously high levels of blood acids that could require hospitalization. The warning comes from the US, but what does this mean for Canada. Our Medical Director, Dr. Tom Elliott, lets us know. […]

READ MORE
Translate »